ROS1-GOPC

GOPC-ROS1 · Variant type: fusion · Fusion partner: GOPC

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Lorlatinib	100.0%	0.0%	97.24
2	Repotrectinib	100.0%	0.0%	84.21
3	Ceritinib	99.6%	0.4%	95.44
4	Entrectinib	99.6%	0.4%	93.69
5	Gilteritinib	99.5%	0.5%	88.97
6	Crizotinib	99.4%	0.6%	91.39
7	Lazertinib	98.6%	1.4%	97.47
8	Pralsetinib	98.5%	1.5%	93.43
9	Brigatinib	98.4%	1.6%	82.96
10	Pacritinib	97.8%	2.2%	88.64
11	Alpelisib	97.2%	2.8%	97.22
12	Osimertinib	96.9%	3.1%	97.24
13	Fostamatinib	95.2%	4.8%	96.74
14	Defactinib	94.2%	5.8%	92.68
15	Axitinib	91.1%	8.9%	93.23
16	Tenalisib	90.9%	9.1%	97.98
17	Pazopanib	89.7%	10.3%	97.49
18	Fedratinib	89.5%	10.4%	96.21
19	Cabozantinib	88.3%	11.7%	92.73
20	Tivozanib	82.8%	17.2%	92.42
21	Selpercatinib	69.8%	30.2%	96.72
22	Abemaciclib	68.1%	31.9%	91.48
23	Capmatinib	60.7%	39.3%	99.75
24	Nintedanib	58.8%	41.2%	90.23
25	Ponatinib	54.4%	45.6%	78.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Lorlatinib	100.0%	—	—
Repotrectinib	100.0%	—	—
Ceritinib	99.6%	—	—
Entrectinib	99.6%	—	—
Gilteritinib	99.5%	—	—
Crizotinib	99.4%	—	—
Lazertinib	98.6%	—	—
Pralsetinib	98.5%	—	—
Brigatinib	98.4%	—	—
Pacritinib	97.8%	—	—
Alpelisib	97.2%	—	—
Osimertinib	96.9%	—	—
Fostamatinib	95.2%	—	—
Defactinib	94.2%	—	—
Axitinib	91.1%	—	—
Tenalisib	90.9%	—	—
Pazopanib	89.7%	—	—
Fedratinib	89.5%	—	—
Cabozantinib	88.3%	—	—
Tivozanib	82.8%	—	—
Selpercatinib	69.8%	—	—
Abemaciclib	68.1%	—	—
Capmatinib	60.7%	—	—
Nintedanib	58.8%	—	—
Ponatinib	54.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 27.6ms